Clinical Scorecard: Corrections to the Methods, Results, and Table 2
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Corrections to the Methods, Results, and Table 2 |
| Key Mechanisms | The correction specifies how annual and mean PFB diagnosis prevalence was calculated and clarifies the sensitivity-analysis wording and Table 2 labels; reported values and study conclusions are unchanged. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- Annual PFB diagnosis prevalence was calculated per 10,000 veterans receiving VHA outpatient care, with 95% CIs.
- Mean prevalence for fiscal years 2016-2022 was calculated overall and by age, and within sex strata according to self-reported race and ethnicity.
- A sensitivity analysis requiring at least 2 PFB encounters separated by 30 days or more found prevalence of 5.6 (95% CI, 5.5-5.7) per 10,000 veterans.
- Prevalence estimates use a denominator-based expression per 10,000 veterans; prevalence ratios are unitless.
- The article was corrected; reported values and study conclusions were not altered.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Veterans receiving VHA outpatient care in fiscal years 2016-2022; the correction provides no prescribing data.
The correction addresses prevalence reporting and does not provide treatment recommendations.
Clinical Best Practices
Related Resources & Content
Based on findings from:
Errors in the Methods, Results, and Table 2
Jama Dermatology, 2026.
https://jamanetwork.com/journals/jamadermatology/fullarticle/2857022
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.